


## PHARMACEUTICAL 2019



## Merck & Co. Inc. Rank 25 of 371







## PHARMACEUTICAL 2019



## Merck & Co. Inc. Rank 25 of 371



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 376% points. The greatest weakness of Merck & Co. Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 505% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	25,875,000
Cost of Goods Sold	13,509,000
Intangible Assets	29,684,000
Liabilities, Current	22,206,000
Liabilities, Non-Current	0
Other Assets	13,787,000
Other Compr. Net Income	-334,000
Other Expenses	2,738,000
Other Liabilities	0
Other Net Income	0
Property and Equipment	13,291,000
Research and Development	9,752,000
Revenues	42,294,000
Selling, General and Administrative Expense	10,102,000

Output Variable	Value in 1000 USD
Assets	82,637,000
Liabilities	22,206,000
Expenses	36,101,000
Stockholders Equity	60,431,000
Net Income	6,193,000
Comprehensive Net Income	6,026,000
Economic Capital Ratio	173%